Press Releases April 23, 2026 08:00 AM

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time

Lantheus Schedules Q1 2026 Earnings Call and Webcast for May 7, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
LNTH

Lantheus Holdings, a leading radiopharmaceutical company, announced it will hold a conference call and webcast on May 7, 2026, to discuss its first quarter 2026 financial results and provide a business update. The event aims to inform investors and stakeholders about the company's recent performance and outlook.

Lantheus to Host First Quarter 2026 Earnings Conference Call and Webcast on May 7, 2026, at 8:00 a.m. Eastern Time
LNTH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lantheus is a leading radiopharmaceutical-focused company with a 70-year history, operating globally with offices in North America and Europe.
  • The earnings call is scheduled for May 7, 2026, at 8:00 a.m. Eastern Time and will include a webcast and replay availability.
  • The announcement highlights the company's commitment to transparency and engaging with investors through timely financial disclosures.

BEDFORD, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, May 7, 2026, to discuss its financial results and provide a business update for the first quarter of 2026.

To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.

A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]

Melissa Downs
Executive Director, External Communications
646-975-2533
[email protected]


Risks

  • The article does not provide specific financial results or guidance, creating uncertainty about the company's actual performance in Q1 2026.
  • As a company operating in the radiopharmaceutical sector, Lantheus faces regulatory, clinical development, and market adoption risks inherent to the healthcare and biotech industries.
  • Global operations expose the company to geopolitical, currency, and market risks across different regions.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026